share_log

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $13

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $13

HC Wainwright & Co.维持对加的夫肿瘤学的买入,将目标股价下调至13美元
Benzinga ·  2023/08/08 07:23

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and lowers the price target from $14 to $13.

HC Wainwright & Co. 分析师Raghuram Selvaraju维持加的夫肿瘤学(纳斯达克股票代码:CRDF)的买入,并将目标股价从14美元下调至13美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发